Synergistic activity of colistin plus rifampin against colistin-resistant kpc-producing klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3990-3993

  Tascini, Carlo ^a   Tagliaferri, Enrico ^a   Giani, Tommaso ^c   Leonildi, Alessandro ^a   Flammini, Sarah ^a   Casini, Beatrice ^b   Lewis, Russell ^e   Ferranti, Simone ^a   Rossolini, Gian Maria ^c,d,f   Menichetti, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEM DERIVATIVE; COLISTIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; RIFAMPICIN; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GENES, BACTERIAL; GENTAMICINS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; RIFAMPIN;

EID: 84880260917     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00179-13     Document Type: Article

References (25)

1. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798.
2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25:682-707.
3. Tóth A, Damjanova I, Puskás E, Jánvári L, Farkas M, Dobák A, Böröcz K, Pászti J. 2010. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur. J. Clin. Microbiol. Infect. Dis. 29:765-769.
4. Giakkoupi P, Papagiannitsis CC, Miriagou V, Pappa O, Polemis M, Tryfinopoulou K, Tzouvelekis LS, Vatopoulos AC. 2011. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J. Antimicrob. Chemother. 66:1510-1513.
5. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPC): an emerging cause of multidrugresistant infection. J. Antimicrob. Chemother. 65:119-125.
6. Tumbarello M, Viale PG, Viscoli C, Trecarichi EA, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55:943-950.
7. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56:2108-2113.
8. Sbrana F, Malacarne P, Viaggi P, Costanzo S, Leonetti S, Leonildi A, Casini B, Tascini C, Menichetti F. 2013. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae in intensive care unit. Clin. Infect. Dis. 56:697-700.
9. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, Themeli-Digalaki K, Tsakris A. 2010. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J. Clin. Microbiol. 48:2271-2274.
10. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. j. Antimicrob. Chemother. 66:946-947.
11. Giani T, Arena F, Cannatelli A, Conte V, Ambretti S, Conaldi P, Luzzaro F, Manso E, Navarra A, Pagani L, Santoriello L, Sarti M, Spanu T, Stefani S, Tascini C, Rossolini GM. 2011. Rapid multifocal emergence of colistin-resistant Klebsiella pneumoniae producing KPC-type carbapenemases (KPC-Kp), Italy, poster C2-669b. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC). American Society for Microbiology, Washington, DC.
12. Clinical and Laboratory Standard Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth ed. CLSI, Wayne, PA.
13. European Committee on Antimicrobial Susceptibility Testing. 2013. Breakpoint tables for interpretation for MICs and zone diameters: version 3.0, valid from 2013-01-01. EUCAST, Basel, Switzerland.
14. Mena A, Plasencia V, García L, Hidalgo O, Ayestarán JI, Alberti S, Borrell N, Pérez JL, Oliver A. 2006. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J. Clin. Microbiol. 44: 2831-2837.
15. Marques MB, Brookings ES, Moser SA, Sonke PB, Waites KB. 1997. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acineterbacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob. Agents Chemother. 41:881-885.
16. European Committee for Antimicrobial Susceptibility Testing. 2000. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. EUCAST definitive document E.Def 1.2. EUCAST, Basel, Switzerland.
17. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132.
18. Elemam A, Rahimian J, Doymaz M. 2010. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 48:3558-3562.
19. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. 2011. Activities of colistin-and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 11:109. doi:10.1186/1471-2334-11-109.
20. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:1165-1172.
21. Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, Menichetti F. 2004. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J. Chemother. 16:282-287.
22. Wareham DW, Bean DC. 2006. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 21:5-10.
23. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. 2012. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob. Agents Chemother. 56:2129-2131.
24. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. 2012. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 56:3395-3398.
25. Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, Oren I. 2011. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 46:1226-1230.